相关实验视频

Updated: Aug 11, 2026

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

MTHFD1表达与小细胞肺癌的发展和化疗放射治疗结果的特定关联

Yujia Hao¹, Ruichun Lu¹, Ying Guo¹

¹From the Department of Respiratory Medicine Second Ward (Hao), JinanThird People's Hospital, Jinan, from the Department of Cadre Healthcare/Geriatrics (Lu), Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, from the Hebei North University (Guo), Zhangjiakou, and from the Department of Pulmonary and Critical Care Medicine (Bao), The Eighth Medical Center of Chinese PLA General Hospital, Beijing, China.

Saudi medical journal

|July 29, 2024

概括

MTHFD1在小细胞肺癌 (SCLC) 中升高,预测化学放射治疗 (CRT) 后的预后较差. 这种生物标志物可以帮助预测SCLC患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

区分小细胞肺癌 (SCLC) 和非小细胞肺癌 (NSCLC) 对于治疗选择至关重要.
识别SCLC的特定生物标志物可以提高诊断准确性和预后预测.
化疗放射治疗 (CRT) 是SCLC的标准治疗方法,但预测治疗反应仍然是一个挑战.

研究的目的:

为了确定区分SCLC和NSCLC的生物标志物.
调查已识别的生物标志物与接受CRT的SCLC患者的预后之间的关联.
探索生物标志物在肺癌细胞放射敏感性中的功能作用.

主要方法:

利用GSE40275数据集来确定SCLC中的潜在目标.
在肺癌组织中使用免疫组织化学 (第1队列) 量化MTHFD1水平.
评估了MTHFD1水平与SCLC患者 (2组) 的CRT治疗结果的相关性,并进行了体外细胞实验.

主要成果:

肺癌组织中MTHFD1水平升高,可以区分SCLC与肺状细胞癌 (LUSC) 和肺腺癌 (LUAD).
高MTHFD1表达与CRT后SCLC患者的预后较差相关,但不是LUSC或LUAD.
在体外,MTHFD1的过度表达在SCLC和NSCLC细胞系中增强了放射电阻.

结论:

MTHFD1表达可以作为SCLC的新和特定的预后生物标志物.
MTHFD1水平可能会预测SCLC患者的化学放射治疗治疗结果.
对MTHFD1作用的进一步研究可能会导致针对SCLC的向治疗策略.

关键词:

卢阿德 (Luad) 的意思是说.在LUSC中使用LUSC.在SCLC中,SCLC是最重要的.生物标志物生物标志物预后预后预后

更多相关视频

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids

Published on: October 21, 2022

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...